Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site

Abiraterone acetate is a first-line therapy for castration-resistant prostate cancer. This prodrug is deacetylated in vivo to abiraterone, which is a potent and specific inhibitor of cytochrome P450 17A1 (CYP17A1). CYP17A1 performs two sequential steps that are required for the biosynthesis of andro...

Descripción completa

Detalles Bibliográficos
Autores principales: Petrunak, Elyse M., Bart, Aaron G., Peng, Hwei-Ming, Auchus, Richard J., Scott, Emily E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023946/
https://www.ncbi.nlm.nih.gov/pubmed/36773804
http://dx.doi.org/10.1016/j.jbc.2023.102999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023946/
https://www.ncbi.nlm.nih.gov/pubmed/36773804
http://dx.doi.org/10.1016/j.jbc.2023.102999

Ejemplares similares